Thursday, November 06, 2014 12:48:39 PM
In other countries, where there is no freedom of the press, the people are blind to what may come but nevertheless those totalitarian regimes take precautions.
Take for example Canada, among 30 other countries. Scared out of their wits even with TKM-Ebola handy?
http://www.washingtonpost.com/blogs/worldviews/wp/2014/11/06/why-are-australia-and-canada-following-north-koreas-lead-on-ebola/
Is there a post-HIV syndrome or post-Herpes(shingles) syndrome?
https://gma.yahoo.com/post-ebola-syndrome-persists-virus-cured-doctor-says-181100681--abc-news-topstories.html
The war against Ebola should be fought over there, in West Africa, in the hotbeds of Ebola and currently there are Ebola vaccine trials in Mali. Hopefully they will help prevent the spread. It is over there where people must be quarantined and treated. It is wise to err on the side of caution, in the least risky manner in a situation (Ebola spread) in which one is uncertain about the consequences.
Currently there is only one small biotech company that may ERRADICATE Ebola from a host and that is NanoViricides, Inc.. We also have a state-of-the-art CGMP Pilot Plant in Connecticut.
http://www.nanoviricides.com/press%20releases/2014/NanoViricides,%20Inc.%20Signs%20CRADA%20for%20Material%20Transfer%20with%20USAMRIID%20for%20Evaluating%20Its%20Anti-Ebola%20Drug%20Candidates.html
www.siliconinvestor.com/subject.aspx?subjectid=55797
I wrote to my senators at the U.S. Congress to exhort them and join senator Richard Blumenthal of CT in his support to speed up efficacy testing of EbolaCide2 at USAMRIID bsl-4 facilities. I also requested streamlining of FDA Regulations (obstacles) of low toxicity and potentially life-saving FluCide? Did you? I did not ask for money for my small biotech company. Don't just gripe about elections and perceptions, do something about it!
We will soon enough find out who is right about efficacy and EbolaCide. And I figure the news media will be asking about what else we have in the drug pipeline.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM